Download PDF
Nervenheilkunde 2015; 34(03): 167-173
DOI: 10.1055/s-0038-1627571
Parkinson
Schattauer GmbH

Schmerzen und Missempfindungen bei Parkinson-Patienten

Pain and sensory complaints in patients with Parkinson’s disease
A. Ceballos-Baumann
1   Abt. für Neurologie und klinische Neurophysiologie mit Parkinson-Fachklinik, Schön Klinik München Schwabing
› Author Affiliations
Further Information

Publication History

eingegangen am: 16 January 2015

angenommen am: 16 January 2015

Publication Date:
22 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Parkinson-Patienten klagen sehr häufig über Schmerzen und Missempfindungen. Das therapeutische Vorgehen zielt zunächst auf eine Optimierung der dopaminergen Medikation, da Schmerzen häufig mit der Akinese und dem Rigor zusammenhängen und mit motorischen Fluktuationen korrelieren. Dabei kommt auch den Eskalationstherapien wie der subkutanen Apomorphin-, der jejunalen Levodopa-Carbidopa-Infusion und der tiefen Hirnstimulation eine Rolle zu. Botulinumtoxin ist hilfreich bei mit Off-Dystonien assoziierten Schmerzen. Der Einsatz von Analgetika einschließlich von Opioiden ist notwendig bei parkinsonunabhängigen Schmerzen oder bei durch Dopaminergika nicht modifizierbare Schmerzen. Opioide können Rigor verstärken und die Entwicklung von Delirien begünstigen.

Summary

Pain and sensory complaints are common among patients with Parkinson’s disease. Despite its high prevalence in Parkinson’s disease the burden of pain is often underestimated, misdiagnosed and not correctly treated. Therapeutic strategies should firstly aim at sufficient dopaminergic stimulation since pain is frequently linked to akinesia, rigidity and may fluctuate similarly to motor signs. In this setting subcutaneous apomorphine or jejunal levodopa/carbidopa infusion and deep brain stimulation will play a role. Botulinum toxin may be helpful in painful dystonic spasms. Analgesics are necessary in Parkinson independent pain or pain which is not modifiable with dopaminergic drugs. Opioids can exacerbate rigidity and produce confusional states.

Schlüsselwörter

Schmerz - chronisches Schmerzsyndrom - Parkinson-Syndrom - Levodopa - Dopaminergika - Restless-legs-Syndrom

Keywords

Pain - Parkinson’s disease - parkinsonism - rest legs syndrom - levodopa
 

  • Literatur

  • 1 Bailbe M. et al. [Improvement in swallowing difficulties treated by subcutaneous apomorphine infusion after deep brain stimulation in Parkinson’s disease]. Rev Neurol (Paris) 2004; 160 (03) 352-3.
    CrossrefGoogle Scholar
  • 2 Barone P. et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009; 24 (11) 1641-9.
    CrossrefGoogle Scholar
  • 3 Boecker H. et al. A PET activation study of sensory processing in Parkinson´s disease and Huntington´s disease. Brain 1999; 122: 1651-65.
    CrossrefGoogle Scholar
  • 4 Born LJ. et al. Cricopharyngeal dysfunction in Parkinson’s disease: role in dysphagia and response to myotomy. Mov Disord 1996; 11 (01) 53-8.
    CrossrefGoogle Scholar
  • 5 Brefel-Courbon C. et al. Comparison of chronic analgesic drugs prevalence in Parkinson’s disease, other chronic diseases and the general population. Pain 2009; 141 (1–2|): 14-8.
    CrossrefGoogle Scholar
  • 6 Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, Montastruc JL, Rascol O. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord 2005; 20 (12) 1557-63.
    CrossrefGoogle Scholar
  • 7 Broen MP, Braaksma MM, Patijn J, Weber WE. Prevalence of pain in Parkinson’s disease: a systematic review using the modified QUADAS tool. Mov Disord 2012; 27 (04) 480-4.
    CrossrefGoogle Scholar
  • 8 Broetz D, Eichner M, Gasser T, Weller M, Steinbach JP. Radicular and nonradicular back pain in Parkinson’s disease: a controlled study. Mov Disord 2007; 22 (06) 853-6.
    CrossrefGoogle Scholar
  • 9 Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson’s disease. Neurology 1989; 39 (10) 1309-14.
    CrossrefGoogle Scholar
  • 10 Cantello R. et al. Analgesic action of methylphenidate on parkinsonian sensory symptoms. Mechanisms and pathophysiological implications. Arch Neurol 1988; 45 (09) 973-6.
    Google Scholar
  • 11 Colosimo C. et al. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol 2010; 257 (01) 5-14.
    CrossrefGoogle Scholar
  • 12 Colosimo C, Salvatori FM. Injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord 2009; 24 (02) 316-7.
    Google Scholar
  • 13 Cury RG. et al. Effects of deep brain stimulation on pain and other nonmotor symptoms in Parkinson disease. Neurology 2014; 83 (16) 1403-9.
    CrossrefGoogle Scholar
  • 14 Decina P, Mukherjee S, Caracci G, Harrison K. Painful sensory symptoms in neuroleptic-induced extrapyramidal syndromes. Am J Psychiatry 1992; 149 (08) 1075-80.
    CrossrefGoogle Scholar
  • 15 Dellapina E. et al. Apomorphine effect on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord 26 (01) 153-7.
    Google Scholar
  • 16 Djaldetti R. et al. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007; 30 (04) 201-5.
    Google Scholar
  • 17 Edwards LL. et al. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol 1993; 33 (05) 490-3.
    CrossrefGoogle Scholar
  • 18 Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov Disord 2000; 15 (01) 167-9.
    CrossrefGoogle Scholar
  • 19 Fietzek UM, Schroeteler FE, Ceballos-Baumann AO. Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin. Mov Disord 2009; 24 (13) 2027-8.
    CrossrefGoogle Scholar
  • 20 Fil A. et al. Pain in Parkinson disease: a review of the literature. Parkinsonism Relat Disord 2013; 19 (03) 285-94 discussion 285..
    CrossrefGoogle Scholar
  • 21 Ford B. Pain in Parkinson’s disease. Clin Neurosci 1998; 05 (02) 63-72.
    CrossrefGoogle Scholar
  • 22 Ford B. Pain in Parkinson’s disease. Mov Disord 2010; 25 (Suppl. 01) S98-103.
    CrossrefGoogle Scholar
  • 23 Ford B, Louis ED, Greene P, Fahn S. Oral and genital pain syndromes in Parkinson’s disease. Mov Disord 1996; 11 (04) 421-6.
    CrossrefGoogle Scholar
  • 24 Gerdelat-Mas A. et al. Levodopa raises objective pain threshold in Parkinson’s disease: A RIII reflex study. J Neurol Neurosurg Psychiatry 2007; 78: 1140-2.
    CrossrefGoogle Scholar
  • 25 Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45 (04) 712-7.
    CrossrefGoogle Scholar
  • 26 Ha AD, Jankovic J. Pain in Parkinson’s disease. Mov Disord 2012; 27 (04) 485-91.
    CrossrefGoogle Scholar
  • 27 https://clinicaltrials.gov/ct2/show/NCT01439100
  • 28 Humm AM. et al. Muscle ischaemia in patients with orthostatic hypotension assessed by velocity recovery cycles. J Neurol Neurosurg Psychiatry 2011; 82 (12) 1394-8.
    CrossrefGoogle Scholar
  • 29 Indaco A, Carrieri PB. Amitriptyline in the treatment of headache in patients with Parkinson’s disease: a double-blind placebo-controlled study. Neurology 1988; 38 (11) 1720-2.
    CrossrefGoogle Scholar
  • 30 Kassubek J. et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurol 2014; 14: 42.
    CrossrefGoogle Scholar
  • 31 Kim HJ, Jeon BS, Paek SH. Effect of deep brain stimulation on pain in Parkinson disease. J Neurol Sci 2011; 310 (1–2): 251-5.
    CrossrefGoogle Scholar
  • 32 Lefaucheur R. et al. Acute genital pain during nonmotor fluctuations improved by apomorphine. Mov Disord 2013; 28 (05) 687-8.
    CrossrefGoogle Scholar
  • 33 Loher TJ. et al. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73 (04) 395-9.
    CrossrefGoogle Scholar
  • 34 Madden MB, Hall DA. Shoulder pain in Parkinson’s disease: a case-control study. Mov Disord 2010; 25 (08) 1105-6.
    CrossrefGoogle Scholar
  • 35 Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: a dystonic phenomenon?. J Neurol Neurosurg Psychiatry 1988; 51 (12) 1503-7.
    CrossrefGoogle Scholar
  • 36 Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson’s disease. Mov Disord 2009; 24 (08) 1233-7.
    CrossrefGoogle Scholar
  • 37 Negre-Pages L, Regragui W, Bouhassira D, Grandjean H, Rascol O. Chronic pain in Parkinson’s disease: The cross-sectional French DoPaMiP survey. Mov Disord 2008; 23 (10) 1361-9.
    CrossrefGoogle Scholar
  • 38 Nunes JC. et al. Prevalence of headache in patients with Parkinson’s disease and its association with the side of motor symptom onset. Neurol Sci 2014; 35 (04) 595-600.
    CrossrefGoogle Scholar
  • 39 Olanow CW. et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13 (02) 141-9.
    CrossrefGoogle Scholar
  • 40 Olson WL, Gruenthal M, Mueller ME, Olson WH. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am J Med 1997; 102 (01) 60-6.
    CrossrefGoogle Scholar
  • 41 Pacchetti C. et al. “Off “ painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord 1995; 10 (03) 333-6.
    CrossrefGoogle Scholar
  • 42 Polo KB, Jabbari B. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann Neurol 1994; 35 (02) 237-9.
    CrossrefGoogle Scholar
  • 43 Putzki N, Maschke M, Drepper J, Diener HC, Timmann D. Effect of functional NMDA-antagonist flupirtine on automatic postural responses in Parkinson’s disease. J Neurol 2002; 249 (07) 824-8.
    CrossrefGoogle Scholar
  • 44 Rana AQ, Depradine J. Abdominal pain: a symptom of levodopa end of dose wearing off in Parkinson’s disease. West Indian Med J 2011; 60 (02) 223-4.
    Google Scholar
  • 45 Reuter I, Ellis CM, Ray KChaudhuri. Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurol Scand 1999; 100 (03) 163-7.
    CrossrefGoogle Scholar
  • 46 Riley D. et al. Frozen shoulder and other shoulder abnormalities in Parkinson´s disease. J Neurol Neurosurg Psych 1988; 52: 63-66.
    Google Scholar
  • 47 Schestatsky P. et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 2007; 69 (23) 2162-9.
    CrossrefGoogle Scholar
  • 48 Schmidt WJ, Schuster G, Wacker E, Pergande G. Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Eur J Pharmacol 1997; 327 (01) 1-9.
    CrossrefGoogle Scholar
  • 49 Schott GD. Pain in Parkinson’s disease. Pain 1985; 22 (04) 407-11.
    CrossrefGoogle Scholar
  • 50 Schroeteler FE. et al. Upright posture in parkinsonian camptocormia using a high-frame walker with forearm support. Mov Disord 2011; 26 (08) 1560-1.
    CrossrefGoogle Scholar
  • 51 Schwarz M, Nolden-Koch M, Purr J, Pergande G, Block F. Antiparkinsonian effect of flupirtine in monoamine-depleted rats. J Neural Transm Gen Sect 1996; 103 (05) 581-90.
    CrossrefGoogle Scholar
  • 52 Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology 1976; 26 (05) 423-9.
    CrossrefGoogle Scholar
  • 53 Stacy M, Hauser R, Oertel W, Schapira A, Sethi K, Stocchi F, Tolosa E. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006; 29 (06) 312-21.
    CrossrefGoogle Scholar
  • 54 Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 2008; 14 (03) 205-212.
    CrossrefGoogle Scholar
  • 55 Storch A. et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2014; 80 (09) 800-9.
    Google Scholar
  • 56 Tinazzi M. et al. Pain and motor complications in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006; 77 (07) 822-5.
    CrossrefGoogle Scholar
  • 57 Tiple D, Fabbrini G, Colosimo C, Ottaviani D, Camerota F, Defazio G, Berardelli A. Camptocormia in Parkinson disease: an epidemiological and clinical study. J Neurol Neurosurg Psychiatry 2009; 80 (02) 145-8.
    CrossrefGoogle Scholar
  • 58 Tison F. et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov Disord 1996; 11 (06) 729-32.
    CrossrefGoogle Scholar
  • 59 Todorova A, Ray KChaudhuri. Subcutaneous apomorphine and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2013; 19 (12) 1073-8.
    CrossrefGoogle Scholar
  • 60 Van Blercom N. Effects of gabapentin on the motor response to levodopa: a double-blind, placebocontrolled, crossover study in patients with complicated Parkinson disease. Clin Neuropharmacol 2004; 27 (03) 124-8.
    CrossrefGoogle Scholar
  • 61 Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord 2001; 16 (02) 252-7.
    CrossrefGoogle Scholar
  • 62 von Coelln R, Raible A, Gasser T, Asmus F. Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord 2008; 23 (06) 889-92.
    CrossrefGoogle Scholar
  • 63 Wallace VC, Chaudhuri KR. Unexplained lower limb pain in Parkinson’s disease: a phenotypic variant of “painful Parkinson’s disease”. Parkinsonism Relat Disord 2013; 20 (01) 122-4.
    Google Scholar
  • 64 Wasner G, Deuschl G. Pains in Parkinson disease--many syndromes under one umbrella. Nat Rev Neurol 2012; 08 (05) 284-94.
    CrossrefGoogle Scholar
  • 65 Zesiewicz TA. et al. Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. Clin Neuropharmacol 2009; 32 (01) 48-50.
    CrossrefGoogle Scholar
  • 66 Fietzek UM, Messner M, Ceballos-Baumann A. Botulinumtoxin – Therapieoption für Patienten mit Parkinson. Nervenheilkunde 2013; 32: 949-953.
    Article in Thieme ConnectGoogle Scholar
  • 67 Schroeteler F. E. Kamptokormie, Anterocollis und Pisa-Syndrom bei Parkinson. Nervenheilkunde 2015; 34: 138-143.
    Article in Thieme ConnectGoogle Scholar